| abstract |
COMPOUND, PHARMACEUTICAL COMPOSITION, USE AND PROCESS FOR COMPOUND PREPARATION. Described are compounds, pharmaceutical compositions comprising such compounds, and methods of employing such compounds to treat or prevent disease or disorders associated with unregulated or abnormal kinase activity, particularly diseases or disorders involving abnormal kinase activity such as Abi, ALK, AMPK, Aurora, Axi, Bcr-AbI, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDKI, CHK2, CKI, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphBl, FES, FGFR1, FGFR2, FGFR3, Fíti, FIt3, FMS, Fyn, GSK3I3, IGF-1R, lKKcx, 1KK13, IR, IRAK4, ITK, JAK2, JAK3, JNKIctI, JNK2a, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEKI-MET2, MEKI-MET2 MKK4, MKK6, MST2, NEK2, NLK, p7OS6K, PAK2, PDGFR, PDGFRcx, PDK1, Pim-2, Plk3, PKA, PKBa, PKCcx, PKCteta, PKD2, c-Raf, RET, ROCK-I, ROCK-li, ROCK-li, Ron, Ros, Rskl, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70. |